Contact this trialFirst, we need to learn more about you.
Cyclin-Dependent Kinase (CDK) Inhibitor
Fadraciclib for Cancer
Recruiting1 awardPhase 1 & 2
Houston, Texas
This trial tests a new oral drug, Fadraciclib, for patients with advanced cancers or lymphomas who have no other treatment options. The drug works by blocking proteins that help cancer cells grow.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service